AU613154B2 - Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants - Google Patents

Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants Download PDF

Info

Publication number
AU613154B2
AU613154B2 AU30243/89A AU3024389A AU613154B2 AU 613154 B2 AU613154 B2 AU 613154B2 AU 30243/89 A AU30243/89 A AU 30243/89A AU 3024389 A AU3024389 A AU 3024389A AU 613154 B2 AU613154 B2 AU 613154B2
Authority
AU
Australia
Prior art keywords
factor xiii
intraventricular hemorrhage
prevention
premature infants
hemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU30243/89A
Other languages
English (en)
Other versions
AU3024389A (en
Inventor
Akira Shirahata
Satoshi Tanaka
Kenichiro Tsumura
Minoru Uchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Publication of AU3024389A publication Critical patent/AU3024389A/en
Application granted granted Critical
Publication of AU613154B2 publication Critical patent/AU613154B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU30243/89A 1988-02-24 1989-02-23 Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants Expired AU613154B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤
JP63-39646 1988-02-24

Publications (2)

Publication Number Publication Date
AU3024389A AU3024389A (en) 1989-08-24
AU613154B2 true AU613154B2 (en) 1991-07-25

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30243/89A Expired AU613154B2 (en) 1988-02-24 1989-02-23 Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants

Country Status (12)

Country Link
US (1) US5114916A (enExample)
EP (1) EP0330049B1 (enExample)
JP (1) JPH01216939A (enExample)
KR (1) KR0137476B1 (enExample)
AT (1) ATE94070T1 (enExample)
AU (1) AU613154B2 (enExample)
CA (1) CA1332352C (enExample)
DE (1) DE68908913T2 (enExample)
DK (1) DK174978B1 (enExample)
ES (1) ES2059588T3 (enExample)
IE (1) IE63656B1 (enExample)
PT (1) PT89802B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
EP0624095B2 (en) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
WO1993020837A1 (fr) * 1992-04-21 1993-10-28 Ajinomoto Co., Inc. Remede contre les plaies
DE69326349T2 (de) * 1992-11-12 2000-03-02 Mayberg, Marc R. Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
JP2008510476A (ja) * 2004-08-27 2008-04-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
US8461302B2 (en) * 2004-11-23 2013-06-11 Zymogenetics, Inc. Purification of recombinant human factor XIII
TWI418564B (zh) * 2005-04-11 2013-12-11 沙凡特藥品公司 利用陽離子界面活性劑之蛋白質純化
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
KR101288027B1 (ko) * 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7869487A (en) * 1986-09-19 1988-03-31 University Of Washington Expression of biologically active factor XIII

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7869487A (en) * 1986-09-19 1988-03-31 University Of Washington Expression of biologically active factor XIII

Also Published As

Publication number Publication date
JPH0378850B2 (enExample) 1991-12-17
PT89802B (pt) 1994-04-29
EP0330049B1 (en) 1993-09-08
DE68908913T2 (de) 1994-01-27
KR890012659A (ko) 1989-09-18
ATE94070T1 (de) 1993-09-15
IE63656B1 (en) 1995-05-31
DE68908913D1 (de) 1993-10-14
US5114916A (en) 1992-05-19
PT89802A (pt) 1989-10-04
EP0330049A2 (en) 1989-08-30
JPH01216939A (ja) 1989-08-30
EP0330049A3 (en) 1991-01-30
CA1332352C (en) 1994-10-11
AU3024389A (en) 1989-08-24
ES2059588T3 (es) 1994-11-16
DK174978B1 (da) 2004-04-05
IE890580L (en) 1989-08-24
DK83889A (da) 1989-08-25
DK83889D0 (da) 1989-02-23
KR0137476B1 (ko) 1998-06-01

Similar Documents

Publication Publication Date Title
US5114916A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
Esmon The regulation of natural anticoagulant pathways
Long et al. Antiserum against tumor necrosis factor enhances lipopolysaccharide fever in rats
JPH02501028A (ja) トロンビンから誘導されたポリペプチド、組成物およびその使用方法
AU722743B2 (en) Stabilized aqueous liquid preparations of blood coagulation factor XIII
CA2091134C (en) Therapeutic agent for threatened abortion
EP0278416B1 (en) Use of human blood coagulation factor xiii for the treatment of ulcerative colitis
AT397615B (de) Arzneimittel enthaltend protein c
US5164373A (en) Therapeutic agent for diabetic gangrene comprising factor XIII
EP0691850B1 (en) Factor xiii for treatment of skin wounds
Tarter et al. A clinical study of the use of intravenous urea in glaucoma
JP2698782B2 (ja) 脳動脈瘤破裂防止剤
Nadal Inhibition of hepatocyte proliferation in vivo by a glycopeptide from rat serum
Boiko et al. Experimental validation for the use of recombinant prourokinase and its immobilized forms in the treatment of postoperative fibrinoid syndrome in ophthalmology
JOHNSON et al. of a Factor VIII Concentrateđ
JPH0495031A (ja) 血栓溶解活性増強剤
Shapiro Clinical disorders of the factor VIII molecule
TH44144A (th) วิธีสำหรับรักษาความผิดปกติของหลอดเลือด